MVA-HIV A vaccine phase I clinical trial

Advisory reports | 13.12.2003 | 031211-02

The study is a phase I clinical trial of a viral vaccine against a strain of the human immunodeficiency virus (HIV-1 Clade A). The vaccine is based on a pox virus strain, ‘Modified Vaccinia Ankara’ (MVA), into which an HIV A sequence (MVA-HIV A) has been inserted. In the trial, HIV-negative study subjects are vaccinated with the genetically modified vaccine, MVA-HIV A. The aim of the trial is to study the safety of three different modes of administration (intramuscular, subcutaneous and intradermal) at three different doses of vaccine. In COGEM’s opinion the phase I clinical trial with the genetically modified vaccine MVA-HIV A poses negligible risks for humans and the environment, as long as the bedclothes and clothing of the patients are disinfected because both can become contaminated if the injection site not properly taped.